Finance

Lists
Why is KLRS down 8,20%?
Dive Deeper
KLRS:NASDAQ
Kalaris Therapeutics Inc
2,35 US$
-8,20%
(-0,21) 1D
8 ოქტ, 11:07:49 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for KLRS...
Open
2,60 US$
High
2,60 US$
Low
2,35 US$
Mkt. cap
55,94 მლნ.
Avg. vol.
72,21 ათ.
Volume
230,00
52-wk high
11,88 US$
52-wk low
2,35 US$
EPS
-2,09 US$
Beta
0,42
Shares outstanding
23,80 მლნ.
No. of employees
20
Open
2,60 US$
High
2,60 US$
Low
2,35 US$
Mkt. cap
55,94 მლნ.
Avg. vol.
72,21 ათ.
Volume
230,00
52-wk high
11,88 US$
52-wk low
2,35 US$
EPS
-2,09 US$
Beta
0,42
Shares outstanding
23,80 მლნ.
No. of employees
20
News stories
From web sources and news partners
The Hollywood Reporter
The Hollywood Reporter
·
3 წუთის წინ
On the Floor as Skydance Tries to Win Over Wall Street
Simply Wall Street
Simply Wall Street
·
18 წუთის წინ
VeriSign (VRSN) Gets A Rating Upgrade, Is It Still 9% Below Fair Value?
goSkagit
goSkagit
·
7 წუთის წინ
Financial Markets Wall Street Skydance
Yahoo Finance
Yahoo Finance
·
2 საათის წინ
ETFs to Benefit as Nasdaq's Breakthrough Still Matters
About Kalaris Therapeutics Inc
CEO-
Employees20
Founded2019
HeadquartersBerkeley Heights, ნიუ-ჯერსი, ამერიკის შეერთებული შტატები
Sector-
Websitekalaristx.com
Analyst ratings
Based on 3 analysts giving stock ratings to KLRS in the past 3 months
Strong buy
Buy
3
Hold
0
Sell
0
12-month forecast
Based on 3 Wall Street analysts offering 12 month price targets for KLRS in the last 3 months.
Highest
Current 2,35 US$
17,00 US$ (+623,40%)
Average
15,50 US$ (+559,57%)
Lowest
14,00 US$ (+495,74%)
Analyst
Recommendation
Action
Price target
Projected
Date
Judah Frommer
Morgan Stanley
Buy
Reiterated
14,00 US$
+495,7%
08/12/2026
Yun Zhong
Wedbush
Buy
Reiterated
17,00 US$
+623,4%
08/11/2026
Lachlan Hanbury Brown
William Blair
Buy
Maintained
-
-
08/11/2026
Tara Bancroft
TD Cowen
Buy
Initiated
-
-
06/15/2026
Jonathan Wolleben
Citizens JMP
Buy
Maintained
25,00 US$
+963,8%
05/13/2026
Biren Amin
Piper Sandler
Hold
Maintained
7,00 US$
+197,9%
03/30/2026
Daniil Gataulin
Chardan Capital
Buy
Initiated
19,00 US$
+708,5%
12/23/2025
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
9,13 მლნ.
7,16 მლნ.
7,57 მლნ.
9,02 მლნ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3,62 მლნ.
3,64 მლნ.
4,26 მლნ.
3,37 მლნ.
Operating expense
12,74 მლნ.
10,80 მლნ.
11,83 მლნ.
12,39 მლნ.
Total operating expenses
12,74 მლნ.
10,80 მლნ.
11,83 მლნ.
12,39 მლნ.
Operating income
-12,74 მლნ.
-10,80 მლნ.
-11,83 მლნ.
-12,39 მლნ.
Other non operating income
847,00 ათ.
803,00 ათ.
977,00 ათ.
871,00 ათ.
EBT including unusual items
-11,89 მლნ.
-10,00 მლნ.
-10,86 მლნ.
-11,52 მლნ.
EBT excluding unusual items
-11,89 მლნ.
-10,00 მლნ.
-10,86 მლნ.
-11,52 მლნ.
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-11,89 მლნ.
-10,00 მლნ.
-10,86 მლნ.
-11,52 მლნ.
Net profit margin
-
-
-
-
Earnings per share
-0,64
-0,44
-0,46
-0,48
Interest and investment income
-
-
-
-
Interest expense
-
-
-
-
Net interest expenses
-
-
-
-
Depreciation and amortization charges
-
-
-
-
EBITDA
-12,74 მლნ.
-10,79 მლნ.
-11,82 მლნ.
-12,38 მლნ.
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google აპები